ADC Therapeutics SA (ADCT) dropped 30.54% to $3.19 after the company released updated results from its LOTIS-7 Phase 1b trial, evaluating ZYNLONTA in combination with a bispecific antibody for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
ADCT said the new data reinforce the potential for a best-in-class regimen, showing encouraging antitumor activity and a manageable safety profile in a heavily pretreated, high-risk population. The company highlighted that the combination demonstrated meaningful responses even in patients who had progressed on multiple prior lines of therapy.
On Friday, ADCT opened at $4.50, reached a high of $4.57, and a low of $3.03, compared to a previous close of $4.60 on the NYSE. Trading volume surged well above average, reflecting unusually heavy activity following the announcement. The stock's 52-week range is $1.31 - $6.04.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.